

Trellus Health plc
("Trellus Health", the "Company" or the "Group")

Result of Annual General Meeting

The Annual General Meeting of Trellus Health plc was held at Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT on 30 June 2025 at 1:00 p.m. (UK time)

All 13 resolutions put to members were passed on a poll. Resolutions 1 to 11 were passed as ordinary resolutions and resolutions 12 and 13 were passed as special resolutions. The full text of the resolutions passed at the Annual General Meeting is set out in the Notice of Meeting, which is available on the Company's website at <https://trellushealth.com/investors>

The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:

Resolution	Votes for	%	Votes against	%	Votes withheld
Resolution 1 (Ordinary)	27,025,398	99.9999	29	0.0001	643,426
Resolution 2 (Ordinary)	20,516,614	75.92	6,508,690	24.08	643,549
Resolution 3 (Ordinary)	26,767,828	99.92	20,253	0.08	880,772
Resolution 4 (Ordinary)	26,290,923	97.87	571,760	2.13	806,170
Resolution 5 (Ordinary)	26,766,798	99.64	95,762	0.36	806,293
Resolution 6 (Ordinary)	26,756,319	99.60	106,364	0.40	806,170
Resolution 7 (Ordinary)	20,506,319	76.34	6,356,364	23.66	806,170
Resolution 8 (Ordinary)	19,851,366	73.90	7,011,317	26.10	806,170
Resolution 9 (Ordinary)	26,942,921	99.69	82,506	0.31	643,426
Resolution 10 (Ordinary)	26,948,536	99.72	76,891	0.28	643,426
Resolution 11 (Ordinary)	26,767,808	99.67	89,875	0.33	811,170
Resolution 12 (Special)	26,756,053	99.71	77,649	0.29	835,151
Resolution 13 (Special)	26,771,655	99.66	90,905	0.34	806,293

The Board notes that Resolutions 2, 7 and 8 received a significant number of votes against those resolutions. In accordance with the QCA Corporate Governance Code, the Board remains committed to maintaining an open and transparent dialogue with shareholders and will continue to consult on any material issues of concern.

As at 30 June 2025, there were 161,508,333 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.

Enquiries:

Trellus Health plc
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder
Jov Bessenger, Chief Financial Officer

<https://trellushealth.com/>
Via Walbrook PR

Singer Capital Markets

Jen Boorer / James Todd / Jalini Kalaravy

Tel: +44 (0)20 7496 3000

Walbrook PR

Paul McManus / Lianne Applegarth /
Alice Woodings

Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
+44 (0)7407 804 654

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

Trellus Health also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGURSRRVKUNOUR